EUVIMEDEUVIMED entdecken
Leitlinie

IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients

Anoma Nellore iD, Kristina Bajema, Katherine Belden, Dean Blumberg, Elizabeth York, Yngve Falck-Ytter, Lindsey Baden

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag115 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Anoma Nellore und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, NYU Langone Health and the NYU Transplant Institute, New York, New York,USA. Hauptthemen laut MEDLINE: Immunocompromised Host, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Infectious Diseases Society of America.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunocompromised individuals face elevated risks of severe COVID-19, yet vaccination guidance for these populations continues to evolve. To support evidence-based decision-making for the 2025–2026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened a multidisciplinary panel to develop rapid guidelines on the use of US-licensed COVID-19 vaccines in adults and children with hematologic malignancies, primary immunodeficiency, autoimmune disease on immunosuppressive therapy, HIV with severe immunosuppression, solid organ transplantation, hematopoietic cell transplantation (HCT), chimeric antigen receptor T-cell therapy (CAR-T), or solid tumor chemotherapy. A systematic evidence review of studies published from June 2024 to July 2025 identified comparative data on vaccine effectiveness and safety. Using the GRADE framework, the panel evaluated 7 observational effectiveness studies and 4 safety-focused studies. Across studies, COVID-19 vaccination was associated with reduced hospitalization (33%–56% effectiveness), critical illness, mortality, and COVID-19–related outpatient or emergency care visits. Serious adverse events were rare, and available evidence did not show consistent increases in exacerbations of underlying immunocompromising conditions. Most studies had short follow-up durations, likely reflecting higher-end estimates of vaccine effectiveness. Given moderate certainty of benefit and low certainty of harm, the panel strongly recommends the 2025–2026 COVID-19 vaccine for all immunocompromised individuals aged ≥6 months, with timing tailored to immunosuppressive therapy, clinical stability, and community transmission levels. Adjunct strategies—including vaccination of household contacts and early antiviral access—remain essential. Research priorities include defining immunologic correlates of protection, evaluating durability, optimizing vaccine timing, and improving real-world effectiveness and safety data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunocompromised HostCOVID-19COVID-19 VaccinesHumansVaccine EfficacySeasonsSARS-CoV-2VaccinationChildAdult

Stichwörter der Autor:innen

adultschildrencoadministrationimmunocompromisedvaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Division of Infectious Diseases, NYU Langone Health and the NYU Transplant Institute, New York, New York,USA.
  • Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
  • Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Division of Pediatric Infectious Disease, Department of Pediatrics, University of California, Davis, School of Medicine, Sacramento, California, USA.
  • Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia, USA.
  • VA Northeast Ohio Healthcare System, Case Western Reserve University, Cleveland, Ohio, USA.

ORCID-Profile: Anoma Nellore

Förderung

  • Infectious Diseases Society of America

Zitieren

APA

Nellore, A., Bajema, K., Belden, K., Blumberg, D., York, E., Falck-Ytter, Y., & Baden, L. (2026). IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag115

Vancouver

Nellore A, Bajema K, Belden K, Blumberg D, York E, Falck-Ytter Y, et al. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag115

BibTeX
@article{Nellore2026,
  author = {Nellore, Anoma and Bajema, Kristina and Belden, Katherine and Blumberg, Dean and York, Elizabeth and Falck-Ytter, Yngve and Baden, Lindsey},
  title = {IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag115}
}
Kostenlos starten →